[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341208-105":59,"doc-detail-341208-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","first-in-human-study-of-the-ataxia-telangiectasia-and-rad3-related-atr-inhibitor-tuvusertib-m1774-as-monotherapy-in-patients-with-solid-tumors","First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors","","Purpose: Tuvusertib (M1774) is a potent, selective, orally administered ATR protein kinase inhibitor. This first-in-human study (NCT04170153) assessed safety, tolerability, maximum tolerated dose (MTD), recommended dose for expansion (RDE), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy as monotherapy. Patients and Methods: Ascending doses were evaluated in 55 metastatic or locally advanced unresectable solid-tumor patients. Dose escalation used PK/PD and safety guided by Bayesian modeling. Results included anemia, neutropenia, lymphopenia, dose-limiting toxicities, exposure-related target engagement, and molecular responses. Conclusions: Safety was manageable and target engagement supported further evaluation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-in-human-study-of-the-ataxia-telangiectasia-and-rad3-related-atr-inhibitor-tuvusertib-m1774-as-monotherapy-in-patients-with-solid-tumors/341208/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-in-human-study-of-the-ataxia-telangiectasia-and-rad3-related-atr-inhibitor-tuvusertib-m1774-as-monotherapy-in-patients-with-solid-tumors/341208.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What did the first-in-human study of tuvusertib (M1774) evaluate?","Question",{"text":113,"@type":114},"It evaluated safety and tolerability, MTD and RDE, pharmacokinetics and pharmacodynamics, and preliminary efficacy of tuvusertib monotherapy in solid-tumor patients (NCT04170153).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were dose-escalation decisions made during the study?",{"text":118,"@type":114},"Ascending doses were guided by a safety monitoring committee using PK, PD, and safety data, supported by a Bayesian 2-parameter logistic regression model.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the recommended dose for expansion (RDE) and how did it compare with MTD?",{"text":122,"@type":114},"The RDE was 180 mg tuvusertib once daily with a 2 weeks on/1 week off schedule, which was better tolerated than the MTD of 180 mg once daily continuously.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341208,1790197363,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors  \nTimothy A. Yap1, Anthony W. Tolcher2, Ruth Plummer3, Jatinder Kaur Mukker4, Marta Enderlin5, Christine Hicking5, Thomas Grombacher5, Giuseppe Locatelli5, Zoltan Szucs6, Ioannis Gounaris6, and Johann [S. de](S. de) Bono7  \nABSTRACT  \n◥  \nPurpose: Tuvusertib(M1774)is a potent, selective, orally administered ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This ﬁrst-in-human study (NCT04170153) evaluated safety, tolerability, maximum tolerated dose (MTD), recommended dose for expansion (RDE), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efﬁcacy oftuvusertib monotherapy.  \nPatients and Methods: Ascending tuvusertib doses were evaluatedin55patients with metastatic or locally advanced unresectable solid tumors. A safety monitoring committee determined dose escalation based on PK, PD, and safety data guided by a Bayesian 2-parameter logistic regression model. Molecular responses (MR) were assessed in circulating tumor DNA samples.  \nResults: Most common grade ≥3 treatment-emergent adverse events were anemia (36%), neutropenia, and lymphopenia (both 7%) . Eleven patients experienced dose-limiting toxicities, most commonly grade 2 (n ¼ 2) or 3 (n ¼ 8) anemia. No persistent  \neffects on blood immune cell populations were observed. The RDE was 180 mg tuvusertib QD (once daily), 2 weeks on/1 week off treatment, which was better tolerated than the MTD (180 mg QD continuously) . Tuvusertib median time to peak plasma concentration ranged from 0.5 to 3.5 hours and mean elimination half-life from 1.2 to 5.6 hours. Exposure-related PD analysis suggested maximum target engagement at ≥ 130 mg tuvusertib QD. Tuvusertib induced frequent MRs in the predicted efﬁcacious dose range; MRs were enriched in patients with radiological disease stabilization, and complete MRs were detected for mutations in ARID1A, ATRX, and DAXX. One patient with platinum-and PARP inhibitor–resistant BRCA wild-type ovarian cancer achieved an unconﬁrmed RECIST v1.1 partial response.  \nConclusions: Tuvusertib demonstrated manageable safety and exposure-related target engagement. Further clinical evaluation oftuvusertib is ongoing.  \nIntroduction  \nThe DNA-damage response (DDR) is a complex network of signaling pathways that monitors and maintains genomic integrity, which is activated in response to all intrinsic and extrinsic DNA damage. Ataxia telangiectasia and Rad3-related (ATR) protein kinase is activated by exposed sections of single-stranded DNA (ssDNA) and is an essential regulator of the replication stress response in actively dividing cells (1, 2) .  \nReplication stress is the slowing or stalling of DNA replication fork progression, one cause of which is endogenous DNA damage resulting from errors during DNA replication (3) . When this occurs, ATR is  \n1University of Texas MD Anderson Cancer Center, Houston, Texas. 2New Experimental Therapeutics (NEXT), San Antonio, Texas. 3Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom. 4EMD Serono, Billerica, Massachusetts. 5The Healthcare Business of Merck KGaA, Darmstadt, Germany. 6Merck Serono Ltd., Feltham, UK, an afﬁliate of Merck KGaA, Darmstadt, Germany. 7Royal Marsden Hospital, Sutton, United Kingdom.  \nCorresponding Author: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030 . E-mail: [tyap@mdanderson.org](tyap@mdanderson.org)  \nClin Cancer Res 2024;30:2057–67  \ndoi: 10.1158/1078-0432 . CCR-23-2409  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4 . 0 International (CC BY-NC-ND 4 . 0) license.  \n􀀁2024The Authors;Published by the American Association for Cancer Research  \nactivated and recruited to the resulting extended stretches of ssDNA. Subsequ","cbCaibPmXH9Uo37z","https://ap.wps.com/l/cbCaibPmXH9Uo37z","pdf",4586488,11,"English","# Abstract\n## Purpose\n## Patients and Methods\n## Results\n## Conclusions\n# Introduction\n## DNA-damage response and ATR\n## Replication stress and therapeutic rationale\n# Translational Relevance","[{\"question\":\"What did the first-in-human study of tuvusertib (M1774) evaluate?\",\"answer\":\"It evaluated safety and tolerability, MTD and RDE, pharmacokinetics and pharmacodynamics, and preliminary efficacy of tuvusertib monotherapy in solid-tumor patients (NCT04170153).\"},{\"question\":\"How were dose-escalation decisions made during the study?\",\"answer\":\"Ascending doses were guided by a safety monitoring committee using PK, PD, and safety data, supported by a Bayesian 2-parameter logistic regression model.\"},{\"question\":\"What was the recommended dose for expansion (RDE) and how did it compare with MTD?\",\"answer\":\"The RDE was 180 mg tuvusertib once daily with a 2 weeks on/1 week off schedule, which was better tolerated than the MTD of 180 mg once daily continuously.\"}]","First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors | PDF",1790040893,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e8a2ea6e78d162f0878c72b89bc962e.webp",983,1286,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/817f02a7369f31b48ca73777bb5d9f0d.webp",982,1285,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cb92645a4e29dccbaabe06e12411348.webp",981,1283,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f878c72afd4f1da0683c74d8fff6a9b.webp",980,1282]